Consortia funded through the IMI Ebola+ Programme Supported by the European Commission
Brings together London School of Hygiene and Tropical Medicine, Inserm, University of Oxford, Le Centre Muraz, ...
IMBRUVICA data presented at the American Society of Hematology Annual Meeting show 79 percent of CLL patients with del 17p were progression-free at 12 months